Viscoelasticity as a measurement of clot structure in poorly controlled type 2 diabetes patients: towards a precision and personalized medicine approach - PubMed (original) (raw)
Viscoelasticity as a measurement of clot structure in poorly controlled type 2 diabetes patients: towards a precision and personalized medicine approach
Etheresia Pretorius et al. Oncotarget. 2016.
Abstract
Objectives: Type 2 diabetes patients (T2D) have a considerably higher cardiovascular risk, which is closely associated with systemic inflammation, and an accompanying pathologic coagulation system. Due to the complexity of the diabetic profile, we suggest that we need to look at each patient individually and particularly at his or her clotting profile; as the healthiness of the coagulation system gives us an indication of the success of clinical intervention.
Results: T2D coagulability varied markedly, although there were no clear difference in medication use and the standards of HbA1c levels.
Research design and methods: Our sample consisted of 90 poorly controlled T2D and 71 healthy individuals. We investigated the medication use and standards of HbA1c levels of T2D and we used thromboelastography (TEG) and scanning electron microscopy (SEM) to study their clot formation.
Conclusion: The latest NIH guidelines suggest that clinical medicine should focus on precision medicine, and the current broad understanding is that precision medicine may in future, provide personalized targets for preventative and therapeutic interventions. Here we suggest a practical example where TEG can be used as an easily accessible point-of-care tool to establish a comprehensive clotting profile analysis for T2D patients; and additionally may provide valuable information that may be used in the envisaged precision medicine approach. Only by closely following each individual patient's progress and healthiness and thereby managing systemic inflammation, will we be able to reduce this pandemic.
Keywords: Pathology Section; coagulation; personalized medicine approach; precision medicine; viscoelasticity; type 2 diabetes.
Conflict of interest statement
The authors (EP and JB) do not have any conflict of interest to declare.
Figures
Figure 1
A. Healthy control plasma coagulation TEG trace showing the different parameters: R: Reaction time, first measurable clot formation; K: Achievement of clot firmness; Angle: Kinetics of clot development; MA: Maximum clot strength; MRTG: Maximum rate of thrombus generation; TMRTG: Time to maximum rate of thrombus generation; TTG: Final clot strength. B. Healthy TEG trace shown in green projected onto the 4 different trace types seen in type 2 diabetes.
Figure 2
A. A typical healthy fibrin fibre net versus B. to E.) typical type 2 diabetes fibrin fiber nets according to the four types identified with TEG. (Numbers in the top left corner correspond with patient number in Table 3). Scale bar: 1 μm.
Similar articles
- Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation.
Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Randeria SN, et al. Cardiovasc Diabetol. 2019 Jun 4;18(1):72. doi: 10.1186/s12933-019-0870-9. Cardiovasc Diabetol. 2019. PMID: 31164120 Free PMC article. - Blood clot parameters: Thromboelastography and scanning electron microscopy in research and clinical practice.
Pretorius E, Swanepoel AC, DeVilliers S, Bester J. Pretorius E, et al. Thromb Res. 2017 Jun;154:59-63. doi: 10.1016/j.thromres.2017.04.005. Epub 2017 Apr 11. Thromb Res. 2017. PMID: 28414934 - Novel Diagnostic and Monitoring Tools in Stroke: an Individualized Patient-Centered Precision Medicine Approach.
de Villiers S, Swanepoel A, Bester J, Pretorius E. de Villiers S, et al. J Atheroscler Thromb. 2016 May 2;23(5):493-504. doi: 10.5551/jat.32748. Epub 2015 Dec 19. J Atheroscler Thromb. 2016. PMID: 26686739 Review. - Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication.
Hu C, Jia W. Hu C, et al. Diabetes. 2018 Jan;67(1):3-11. doi: 10.2337/dbi17-0013. Diabetes. 2018. PMID: 29263166 Review. - Noncitrated whole blood is optimal for evaluation of postinjury coagulopathy with point-of-care rapid thrombelastography.
Kashuk JL, Moore EE, Le T, Lawrence J, Pezold M, Johnson JL, Cothren CC, Biffl WL, Barnett C, Sabel A. Kashuk JL, et al. J Surg Res. 2009 Sep;156(1):133-8. doi: 10.1016/j.jss.2009.03.046. Epub 2009 May 3. J Surg Res. 2009. PMID: 19577246
Cited by
- Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation.
Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Randeria SN, et al. Cardiovasc Diabetol. 2019 Jun 4;18(1):72. doi: 10.1186/s12933-019-0870-9. Cardiovasc Diabetol. 2019. PMID: 31164120 Free PMC article. - Evaluation of Coagulation Profile in Children with Type 1 Diabetes Mellitus Using Rotational Thromboelastometry.
Binay C, Bozkurt Turhan A, Simsek E, Bor O, Akay OM. Binay C, et al. Indian J Hematol Blood Transfus. 2017 Dec;33(4):574-580. doi: 10.1007/s12288-017-0793-0. Epub 2017 Feb 28. Indian J Hematol Blood Transfus. 2017. PMID: 29075072 Free PMC article. - Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, Rajaratnam K, Watson BW, Kell DB. Pretorius E, et al. Cardiovasc Diabetol. 2022 Aug 6;21(1):148. doi: 10.1186/s12933-022-01579-5. Cardiovasc Diabetol. 2022. PMID: 35933347 Free PMC article. - The stabilizing effect of an oligomeric proanthocyanidin on red blood cell membrane structure of poorly controlled Type II diabetes.
Visser J, van Staden PJ, Soma P, Buys AV, Pretorius E. Visser J, et al. Nutr Diabetes. 2017 May 15;7(5):e275. doi: 10.1038/nutd.2017.25. Nutr Diabetes. 2017. PMID: 28504711 Free PMC article. - Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare.
Mamoshina P, Ojomoko L, Yanovich Y, Ostrovski A, Botezatu A, Prikhodko P, Izumchenko E, Aliper A, Romantsov K, Zhebrak A, Ogu IO, Zhavoronkov A. Mamoshina P, et al. Oncotarget. 2017 Nov 9;9(5):5665-5690. doi: 10.18632/oncotarget.22345. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464026 Free PMC article.
References
- Chikowore T, Conradie KR, Towers GW, van Zyl T. Common Variants Associated with Type 2 Diabetes in a Black South African Population of Setswana Descent: African Populations Diverge. Omics. 2015;19(10):617–626. - PubMed
- Camara A, Balde NM, Sobngwi-Tambekou J, Kengne AP, Diallo MM, Tchatchoua AP, Kake A, Sylvie N, Balkau B, Bonnet F, Sobngwi E. Poor glycemic control in type 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c test. Diabetes Res Clin Pract. 2015;108(1):187–192. - PubMed
- CDC National Diabetes Statistics Report. Centers for Disease Control and Prevention. 2014 2016 May; http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html Accessed.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical